Review article: The medical management of Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 10, Issue 1, 1996, Pages 1-22

  Elton, E ^a   Hanauer, S B ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BALSALAZIDE; CORTICOSTEROID; CYCLOSPORIN A; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; OLSALAZINE; SALAZOSULFAPYRIDINE;

ADVERSE DRUG REACTION; CROHN DISEASE; DRUG ABSORPTION; HUMAN; INFLAMMATION; INTESTINE ABSORPTION; NUTRITION; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW;

EID: 0030064095     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.1996.tb00173.x     Document Type: Review

References (264)

1. Sachar DB, Andrews HA, Farmer RG, et al. Proposed classification of patient subgroups in Crohn's disease. Gas Intern 1992; 5: 141-54.
2. Meyers S, Janowitz HD. 'Natural history' of Crohn's disease. An analytic review of the placebo lesson. Gastroenterology 1984; 87: 1189-92.
3. Schroder H, Campbell DES. Absorption, metabolism and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther 1972; 13: 539-51.
4. Peppercorn MA, Goldman P. Distribution studies of salicylazosulfapyridine and its metabolites. Gastroenterology 1973; 64: 240-5.
5. Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther 1972; 181: 555-62.
6. Das KM, Eastwood MA. Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease. Clin Pharmacol Ther 1975; 18: 514-20.
7. Schroder H, Price-Evans DA. Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects. Gut 1972; 13: 278-84.
8. Azad-Khan AH, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulfasalazine. Lancet 1977; 2: 892-5.
9. Gaginella TS, Walsh RE. Sulfasalazine: multiplicity of action. Dig Dis Sci 1992; 37: 801-12.
10. Greenfield SM, Punchard NA, Teare JP, Thompson RPH. The mode of action of the aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther 1993; 7: 369-83.
11. Hawkey CJ, Truelove SC. Inhibition of prostaglandin synthetase in human rectal mucosa. Gut 1983; 234: 213-7.
12. Hoult JRS, Moore PK. Sulphasalazine is a potent inhibitor of prostaglandin 15-hydroxydehydrogenase: possible basis for therapeutic action in ulcerative colitis. Br J Pharmacol 1978; 64: 6-8.
13. Rhodes JM, Bartholomew TC, Jewell DP. Inhibition of leucocyte motility by drugs used in ulcerative colitis. Gut 1981: 22: 642-7.
14. Bjarnason I, Hayllar J, MacPherson AJ, Russell AS. Side effects of nonsteroidal antiinflammatory drugs on the small and large intestine in humans. Gastroenterology 1993; 104: 1832-47.
15. Rask-Madsen J, Bukhave K, Laursen LS, Lauritsen K. 5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease. Agents Actions 1992: (Special Conference Issue): C37-46.
16. Eliakim R, Rachmilewitz D. Inflammatory mediators and the pathogenesis of inflammatory bowel disease. Ital J Gastroenterol 1992; 24: 361-8.
17. Verspaget HW, Mulder TP, Van der Sluys Veer A, Pena AS, Lamers CB. Reactive oxygen metabolites and colitis: a disturbed balance between damage and protection. A selective review. Scand J Gastroenterol 1991; Suppl 188: 44-51.
18. Simmonds NJ, Rampton DS. Inflammatory bowel disease: a radical view. Gut 1993; 34: 865-8.
19. Hawkey CJ, Mahida YR, Hawthorne AB. Therapeutic interventions in gastrointestinal disease based on an understanding of inflammatory mediators. Agents Actions 1992; (Special Conference Issue): C22-6.
20. Summers RW, Switz DM, Sessions JT Jr. et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979; 77: 847-69.
21. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 249-66.
22. Anthonisen P, Barany F, Folkenborg O, et al. The clinical effect of salazosulphapyridine (Salazopyrin®) in Crohn's disease. Scand J Gastroenterol 1974; 9: 549-54.
23. Van Hess PAM, Van Lier HJJ, Van Elteren PH, et al. Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study. Gut 1981; 22: 404-9.
24. Baron JH, Bennett PN, Lennard Jones JE, et al. Sulphasalazine in asymptomatic Crohn's disease: a multicentre trial. Gut 1977; 18: 69-72.
25. Wenckert A, Kristensen M, Ekland AE, et al. The long-term prophylactic effect of salazosulphapyridine (Salazopyrin®) in primarily resected patients with Crohn's disease. Scand J Gastroenterol 1978; 13: 161-7.
26. Ewe K, Herfarth C, Makhow H, Jesdinsky HJ. Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial. Digestion 1989; 42: 224-32.
27. Steinhart HA, Hemphill D, Greenberg R. Sulfasalazine and mesalazine for maintenance therapy of Crohn's disease: a meta-analysis. Am J Gastroenterol 1994; 89: 216-24.
28. Nielsen OH. Sulfasalazine intolerance: a retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. Scand J Gastroenterol 1982; 17: 389-93.
29. Taffet SL, Das KM. Sulfasalazine: adverse effects and desensitization. Dig Dis Sci 1983; 28: 833-42.
30. Singleton JW, Law DH, Kelly ML, et al. National cooperative Crohn's disease study: adverse reactions to study drugs. Gastroenterology 1979; 77: 870-82.
31. Van Hees PAM, Van Elferen LW, Van Rossum JM, Von Tongeren J. Haemolysis during salicylazosulfapyridine therapy. Am J Gastroenterol 1978; 70: 501-5.
32. Das KM, Eastwood MA, McManus JP, Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973; 289: 491-5.
33. Maddocks JL, Slater DN. Toxic epidermal necrolysis, agranulocytosis, and erythroid hypoplasia associated with sulphasalazine. J R Soc Med 1980; 73: 587-8.
34. Das KM, Sternlieb I. Salicylazosulfapyridine in inflammatory bowel disease. Am J Dig Dis 1975; 20: 971-6.
35. Hensen EJ, Class EH, Vermer BJ. Drug-dependent binding of circulating antibodies in drug-induced toxic epidermal necrolysis. Lancet 1981; 2: 151-2.
36. Block MB, Genant HK, Kirsner JB. Pancreatitis as an adverse reaction to salicylazosulfapyridine. N Engl J Med 1970; 282: 380-2.
37. Rubin R. Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis. Am J Gastroenterol 1994; 89: 789-91.
38. Kanner RS, Tedesco FJ, Kalser MH. Azulfidine (Sulfasalazine)-induced hepatic injury. Am J Dig Dis 1978; 23: 956-8.
39. Callen J, Soderstrom RM. Granulomatous hepatitis associated with salicylazosulfapyridine therapy. South Med J 1978; 71: 1159-60.
40. Namias A, Shalotra K, Donowitz M. Reversible sulfasalazine-induced granulomatous hepatitis. J Clin Gastroenterol 1981; 3: 193-5.
41. Gulley RN, Mirza A, Kelly CE. Hepatotoxicity of salicylazosulfapyridine: a case report and review of the literature. Am J Gastroenterol 1979; 72: 561-4.
42. Camus P, Piard F, Ashcroft T, Gal A, Colby T. The lung in inflammatory bowel disease. Medicine 1993; 72: 151-83.
43. Tydd TE. Sulfasalazine lung. Med J Aust 1976; 1: 570-5.
44. Beliner S, Neeman A, Shoenfeld Y, et al. Salazopyrin-induced eosinophilic pneumonia. Respiration 1980; 39: 119-20.
45. Wang KK, Bowyer BA, Fleming RC, Schroeder KW. Pulmonary infiltrates and eosinophilia associated with sulfasalazine. Mayo Clin Proc 1984; 59: 343-6.
46. Hamadeh MA, Atkinson J, Smith LJ. Sulfasalazine-induced pulmonary disease. Chest 1992; 101: 1033-7.
47. Griffiths ID, Kane SP. Sulfasalazine-induced lupus syndrome in ulcerative colitis. BMJ 1977; 2: 1188-9.
48. Reid J, Holt S, Housley E, Snedden DJ. Raynaud's phenomenon induced by sulfasalazine. Postgrad Med J 1980; 56: 106-7.
49. Jamshidi K, Arlander T, Gracia MC, Windschitl HW, Swaim WR. Azulfidine agranulocytosis with bone marrow, megakaryocytosis, histiocytosis and plasmacytosis. Minn Med 1972; 55: 545-8.
50. Davies GE, Palek J. Selective erythroid and megakaryocytic aplasia after sulfasalazine administration. Arch Intern Med 1980; 130: 1122.
51. Wallace IW. Neurotoxicity associated with a reaction to sulfasalazine. Practitioner 1970; 204: 850-1.
52. Schoonjans R, Mast A, Van Den Abeele G, et al. Sulfasalazine-associated encephalopathy in a patient with Crohn's disease. Gastroenterology 1993; 88: 1759-63.
53. Werlin SL, Grand RJ. Bloody diarrhoea: a new complication of sulfasalazine. J Pediatr 1978; 92: 450-1.
54. Schwartz AG, Targan SR, Saxon A, Weinstein WM. Sulfasalazine-induced exacerbation of ulcerative colitis. N Engl J Med 1982; 306: 409-19.
55. Franklin JL, Rosenberg IH. Impaired folic acid absorption in inflammatory bowel disease: effects of salicylazosulfapyridine (azulfidine). Gastroenterology 1973; 64: 517-25.
56. Levi AJ, Fischer AM, Hughes K, Hendry WF. Male infertility due to sulfasalazine. Lancet 1979; 2: 639-40.
57. Toth A. Reversible toxic effect of salicylazosulfapyridine on semen quality. Fertil Steril 1979; 31: 538-40.
58. Collen MJ. Azultidine-induced oligospermia. Am J Gastroenterol 1980; 74: 441-2.
59. Taffet SL, Das KM. Sulfasalazine: adverse effects and desensitization. Dig Dis Sci 1983; 28: 833-42.
60. Korelitz BI, Present DH, Rubin PH, Fochios SE. Desensitization to sulfasalazine after hypersensitivity reactions in patients with inflammatory bowel disease. J Clin Gastroenterol 1984; 6: 27-31.
61. Purdy BH, Philips DM, Summers RW. Desensitization for sulfasalazine skin rash. Ann Intern Med 1984; 100: 512-4.
62. Mogadam M, Dobbins WC, Korelitz BI, Ahmed SW. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology 1981; 80: 72-6.
63. Willoughby CP, Truelove SC. Ulcerative colitis and pregnancy. Gut 1980; 21: 469-74.
64. Miller JP. Inflammatory bowel disease in pregnancy: a review. J R Soc Med 1986; 79: 221-5.
65. Jarnerot G, Into-Malberg MB. Sulphasalazine treatment during breast feeding. Scand J Gastroenterol 1979; 14: 869-71.
66. Klotz U, Maier K, Fischer G, Heinkel K. Therapeutic efficacy of sulfasalazine and its metabolism in patients with ulcerative colitis and Crohn's disease. N Engl J Med 1980; 303: 1499-502.
67. Willoughby CP, Aronson JK, Agback H, Bodin NO, Truelove SC. Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a possible new drug for ulcerative colitis. Gut 1982; 23: 1081-7.
68. Chan RP, Pope DJ, Gilbert AP, Sacra PJ, Baron JH, Lennard-Jones JE. Studies of two novel sulfasalazine analogues, ipsalazide and balsalazide. Dig Dis Sci 1983; 28: 609-15.
69. Rijk MC, Van Schaik A, Van Tongeren JHM. Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea. Scand J Gastroenterol 1992; 27: 863-8.
70. Laursen SL, Stokholm M, Bukhave K, Rask-Madsen J, Lauritsen K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 1990; 31: 1271-6.
71. Hardy JG, Harvey WJ, Sparrow RA, et al. Localization of drug release sites from an oral sustained-release formulation of 5-ASA (Pentasa®) in the gastrointestinal tract using gamma scintigraphy. J Clin Pharmacol 1993; 33: 712-8.
72. Mahida YR, Jewell DP. Slow-release 5-amino-salicylic acid (Pentasa®) for the treatment of active Crohn's disease. Digestion 1990; 45: 88-92.
73. Rasmussen SN, Lauritsen K, Tage-Jensen U. et al. 5-Aminosalicylic acid in the treatment of Crohn's disease : a 16-week double-blind, placebo-controlled, multicentre study with Pentasa.® Scand J Gastroenterol 1987; 22: 877-83.
74. Singleton JW, Hanauer SB, Gitnick GL. et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Gastroenterology 1993; 104: 1293-301.
75. Maier K, Frühmorgen P, Bode JC, Heller TN, Guisbert UB, Klotz U. Successful management of chronic inflammatory gut disease with oral 5-aminosalicylic acid. Dtsch Med Wochenschr 1986; 110: 363-8.
76. Martin R, Sutherland L, Beck IT, et al. Comparative efficacy and safety of oral mesalazine (Salofalk®) versus prednisolone in the short-term treatment of active Crohn's disease: a Canadian multicenter controlled trial. Can J Gastroenterol 1990; 4: 452-7.
77. International Mesalazine Study Group. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. Aliment Pharmacol Ther 1990; 4: 55-64.
78. Gendre JP, Mary JY, Florent C, et al. Oral mesalamine (Pentasa®) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Group d'Études Therapeutiques des Affections Inflammatoires Digestives (GETAID). Gastroenterology 1993; 104: 435-9.
79. Prantera C, Pallone F, Brunetti G, Cottone M, Miglioli M, and the Italian IBD Study Group. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. Gastroenterology 1992; 103: 363-8.
80. Bondesen S and the Danish 5-ASA Group. Mesalazine (Pentasa®) prophylaxis in Crohn's disease: a multicenter controlled trial. Scand J Gastroenterol 1991; Suppl 183: 68 (abstract F44).
81. Fiasse R, Fontaine F, Vanheuverzwyn R. Prevention of Crohn's disease recurrences after intestinal resection with Eudragit-L-coated 5-aminosalicylic acid: preliminary results of a 1-year double-blind placebo-controlled study. Gastroenterology 1991; 100: A208.
82. Wellman W, Schroder U. New oral preparations for maintenance therapy in Crohn's disease. Can J Gastroenterol 1988; 2A: 71A-2A.
83. Bresci G, Petrucci A, Banti S. 5-Aminosalicylic acid in the prevention of relapses of Crohn's disease in remission: a long-term study. Int J Clin Pharmacol Res 1991; 11: 200-2.
84. Caprilli R, Anreoli A, Capurso L, et al. Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of postoperative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Aliment Pharmacol Ther 1994; 8: 35-43.
85. Brignola C, Cottone M, Pera A, et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Gastroenterology 1995; 108: 345-9.
86. Brignola C, Iannone P, Pasquali S, et al. Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease. Dig Dis Sci 1992; 37: 29-32.
87. Florent C, Cortot A, Quandale P, et al. Placebo-controlled trial of Claversal® in the prevention of early endoscopic relapse after 'curative' resection for Crohn's disease. Gastroenterology 1992; 102: A623.
88. Messori A, Brignola C, Trallori G, et al. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis. Am J Gastroenterol 1994; 89: 692-8.
89. Thompson ABR, Review article: New developments in the use of 5-aminosalicylic acid preparations with inflammatory bowel disease. Aliment Pharmacol Ther 1991; 5: 449-70.
90. Rao SS, Cann PA, Holdsworth CD. Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant to sulphasalazine. Scand J Gastroenterol 1987; 22: 332-6.
91. Giaffer MH, O'Brien CJ, Holdsworth CD. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine. Aliment Pharmacol Ther 1992; 6: 51-9.
92. Small RE, Schraa CC. Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease. Pharmacotherapy 1994; 14: 385-98.
93. Brimblecombe R. Mesalazine: a global safety evaluation. Scand J Gastroenterol 1990; Suppl 172: 66.
94. Fiorentini MT, Fracchia M, Calatola G, Barlotta A, de la Pierre M. Acute pancreatitis during oral 5-aminosalicylic acid therapy. Dig Dis Sci 1990; 35: 1180-2.
95. Abdullah AM, Scott RB, Martin SR. Acute pancreatitis secondary to 5-aminosalicylic acid in a child with ulcerative colitis. J Pediatr Gastroenterol Nutr 1993; 17: 441-4.
96. Radke M, Bartolamaeus G, Müller M, Richter I. Acute pancreatitis in Crohn's disease due to 5-ASA therapy. J Pediatr Gastroenterol Nutr 1993; 16: 337-9.
97. Coumaros D, Georges C, Zerbe S. Salicylazosulfapyridine (SASP) hepatitis: role of 5-aminosalicylic acid (5-ASA). Scand J Gastroenterol 1989; Suppl 158: 132-3.
98. Hautekeete ML, Bourgeois N, Potvin P, et al. Hypersensitivity with hepatotoxicity to mesalazine after hypersensitivity to sulfasalazine. Gastroenterology 1992; 103: 1925-7.
99. Legros V, Saveuse H, Lesur G, Brion N. Lung and skin hypersensitivity to 5-aminosalicylic acid. BMJ 1991; 1: 970.
100. Reinoso MA, Schroeder KW, Pisani RJ. Lung disease associated with orally administered mesalamine for ulcerative colitis. Chest 1992; 101: 1469-70.
101. Lim AG, Hine KR. Fever, vasculitic rash, arthritis, pericarditis, and pericardial effusion after mesalazine. BMJ 1994; 308: 113.
102. Kristensen KS, Hoegholm A, Bohr L, et al. Fatal myocarditis associated with mesalazine. Lancet 1990; 1: 605.
103. Bilyard KG, Joseph EC, Metcalf R. Mesalazine: an overview of key preclinical studies. Scand J Gastroenterol 1990; Suppl 172: 52-5.
104. Novis BH, Korzets Z, Chen P, et al. Nephrotic syndrome after treatment with 5-aminosalicylic acid. BMJ 1988; 296: 1442.
105. Riley SA, Mani V, Goodman MJ, et al. Comparison of delayed release 5-aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut 1988; 29: 669-74.
106. Riley SA, Lloyd DR, Mani V. Tests of renal function in patients with quiescent colitis: effects of drug treatment. Gut 1992; 33: 1348-52.
107. Raimundo AH, Patil DH, Frost PG, et al. Effects of olsalazine and sulphasalazine on jejunal and ileal water and electrolyte absorption in normal human subjects. Gut 1991; 32: 270-4.
108. Wadworth AN, Fitton A. Olsalazine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease. Drugs 1991; 41: 647-64.
109. Berglindh T, Landstrom E, Bergqvist E. Induction of and adaptation to olsalazine-induced intestinal volume load. Scand J Gastroenterol 1988; Suppl 148: 24-8.
110. Habal FM, Hui G, Greenberg GR. Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy: safety and clinical course. Gastroenterology 1993; 105: 1057-60.
111. Trallori G, d'Albasio G, Bardazzi G, et al. 5-aminosalicylic acid in pregnancy: clinical report. Ital J Gastroenterol 1994; 26: 75-8.
112. Miller LG, Hopkinson JM, Motil KJ, Corboy JE, Andersson S. Disposition of olsalazine and metabolites in breast milk. J Clin Pharmacol 1993; 33: 703-6.
113. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report of a therapeutic trial. BMJ 1955; 2: 1041-8.
114. 2 inhibitor which prevents prostaglandin generation. Nature 1979; 278: 456-9.
115. Hawthorne AB, Hawkey CJ. Immunosuppressive drugs in inflammatory bowel disease: a review of their mechanisms of efficacy and place in therapy. Drugs 1989; 38: 267-88.
116. Sandle GI, Hayslett JP, Binder HJ. Effect of glucocorticoids on rectal transport in normal subjects and patients with ulcerativc colitis. Gut 1986; 27: 309-16.
117. Cooke WT, Fielding JF. Corticosteroid or corticotropin therapy in Crohn's disease (regional enteritis). Gut 1970; 11: 921-7.
118. Jones JH, Lennard-Jones JF. Corticosteroids and corticotropin in the treatment of Crohn's disease. Gut 1966; 181-7.
119. Rijk MCM, Van Hogezand RA, Van Lier HJJ, Tongeren JHM. Sulphasalazine and prednisone compared with sulphasalazine for treating acting Crohn disease. Ann Intern Med 1991; 114; 445-50.
120. Brignola C, Campieri M, Farruggia P, et al. The possible utility of steroids in the prevention of relapses of Crohn's disease in remission. J Clin Gastroenterol 1988; 10: 631-4.
121. Smith RC, Rhodes J, Heatley RV, et al. Low dose steroids and clinical relapse in Crohn's disease: a controlled trial. Gut 1978; 19: 606-10.
122. Swartz SL, Dluhy RG. Corticosteroids: clinical pharmacology and therapeutic use. Drugs 1978; 16: 238-55.
123. Dujorne CA, Azarnoff DL. Clinical complications of corticosteroid therapy. Med Clin North Am 1973; 57: 1331-42.
124. Shapiro SC, Rothstein FC, Newman AJ, Fletcher B, Halpin TC. Multifocal osteonecrosis in adolescents with Crohn's disease: a complication of therapy? J Pediatr Gastroenterol Nutr 1985; 4: 502-6.
125. Vakil N, Sparberg M. Steroid-related osteonecrosis in inflammatory bowel disease. Gastroenterology 1989; 96: 62-6.
126. Compston JE, Judd D, Crawley EO, et al. Osteoporosis in patients with inflammatory bowel disease. Gut 1978; 28: 410-5.
127. Conn HO, Blitzer BL. Non-association of adrenocorticosteroid therapy and peptic ulcer. N Engl J Med 1976; 294: 473-9.
128. Seyrig JA, Jian R, Modigliani R, et al. Idiopathic pancreatitis associated with inflammatory bowel disease. Dig Dis Sci 1989; 30: 1121-6.
129. Hall RCW, Popkin MK, Stickney SK, Gardner ER. Presentation of the steroid psychoses. J Nerv Ment Dis 1979; 167: 229-36.
130. Tripathi RC, Kirschner BS, Kipp M, et al. Corticosteroid treatment for inflammatory bowel disease in paediatric patients increases intraocular pressure. Gastroenterology 1992; 102: 1957-61.
131. DeCosta EJ, Abelman MA. Cortisone and pregnancy. Am J Obstet Gynecol 1952; 64: 746-7.
132. Bongiovanni AM, McPadden AJ. Steroids during pregnancy. and possible fetal consequences. Fertil Steril 1960; 11: 181-6.
133. Barocco PJ, Korelitz BI. The influence of inflammatory bowel disease and its treatment on pregnancy and fetal outcome. J Clin Gastroenterol 1984; 6: 211-16.
134. Dahlberg E, Thalen A, Brattsand R, et al. Correlation between chemical structure, receptor binding, and biological activity in some novel, highly active, 16α, 17α-acetyl-substituted glucocorticoids. Mol Pharmacol 1984; 25: 70-8.
135. Brattsand R. Overview of newer glucocorticosteroid preparations for inflammatory bowel disease. Can J Gastroenterol 1990; 4: 407-14.
136. Greenberg GR, Feagan BG, Martin F, et al. and the Canadian Inflammatory Bowel Disease Study Group. Oral budesonide for active Crohn's disease. N Engl J Med 1994; 331: 836-41.
137. Rutgeerts P, Löfberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331: 842-5.
138. Lofberg R, Rutgeerts P, Malchow H, et al. Budesonide CIR for maintenance of remission in ileocecal Crohn's disease. A European multicenter placebo controlled trial. Gastroenterology 1994; 106: A722.
139. Greenberg G, Feagan B, Martin F, et al. Oral budesonide as maintenance for Crohn's disease. [Abstract.] Gastroenterology 1995; 108: A827.
140. Lofberg R. Clinical review: New steroids for inflammatory bowel disease. Inflamm Bowel Dis (CCFA Journal) 1995; 1: 135-41.
141. Sartor RB, Bender DE, Allen JB, et al. Chronic experimental enterocolitis and extraintestinal inflammation are T lymphocyte dependent. Gastroenterology 1993; 104: 775A.
142. Matsuura T, West GA, Youngman KR, Klein JS, Fiocchi C. Immune activation genes in inflammatory bowel disease. Gastroenterology 1993; 104: 448-58.
143. Pallone F, Fais S. Squarcia O, Biancone L, Boirivant M. Activation of peripheral blood and intestinal lamina propria lymphocytes in Crohn's disease. In vivo state of activation and in vitro response to stimulation as defined by the expression of early activation antigens. Gut 1987; 28: 745-53.
144. Raedler A, Fraenkel S, Klose G. et al. Involvement of the immune system in the pathogenesis of Crohn's disease: expression of the T9 antigen on peripheral immunocytes correlated with the severity of disease. Gastroenterology 1985; 88: 978-83.
145. Beagley KW, Elson CO. Cells and cytokines in mucosal immunity and inflammation. Gastroenterol Clin North Am 1992; 21: 347-66.
146. Campbell AC, Skinner JM, Hersey P, et al. Immunosuppression in the treatment of inflammatory bowel disease II. The effects of azathioprine on lymphoid cell populations in a double-blind trial in ulcerative colitis. Clin Exp Immunol 1976; 24: 249-58.
147. Leman B, Shanahan F, Targan S. Serial study of immunologic alterations in patients with IBD on long-term treatment with 6-MP: effect on CTL. Gastroenterology 1988; 94: A255.
148. Klein M, Binder HJ, Mitchell M, Aaronson R, Spino H. Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology 1974; 66: 916-22.
149. Rosenberg JL, Levin B, Wall AJ, Kirsner JB. A controlled trial of azathioprine in Crohn's disease. Am J Dig Dis 1975; 20: 721-6.
150. Rhodes J, Bainton D, Beck P, et al. Controlled trial of azathioprine in Crohn's disease. Lancet 1971; 2: 1273-6.
151. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long term randomized double blind study. N Engl J Med 1980; 302: 981-7.
152. Ewe K, Press AG, Singe CC, et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993; 105: 367-72.
153. Colonna T, Korelitz BI. The role of leucopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease. Am J Gastroenterol 1994; 89: 362-6.
154. O'Donoghue DP, Dawson AM, Powell-Tuck J, Brown RL, Lennard-Jones JE. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet 1978; 2: 955-7.
155. Willoughby JMT, Kumar PJ, Beckett J, Dawson AM. Controlled trial of azathioprine in Crohn's disease. Lancet 1971; 2: 994-7.
156. Singleton JW, Law DH, Kelley ML, Mekhjian HS, Sturdevant RA. National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology 1979; 77: 870-82.
157. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111: 641-9.
158. Haber CJ, Meltzer SJ, Present DH, Korelitz BI. Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterology 1986; 91: 982-96.
159. Gross R, Scapa E. Hepatotoxicity of 6-mercaptopurine in Crohn's disease. Am J Gastroenterol 1992; 87: 1885-6.
160. Bernstein CN, Artinian L, Anton PA, Shanahan F. Low-dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicity. Dig Dis Sci 1994; 39: 1638-41.
161. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34: 1081-5.
162. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukemia. Lancet 1990; 336: 225-9.
163. Bradley PP, Warden GD, Maxwell JG, et al. Neutropenia and thrombocytopenia in renal allograft recipients treated with trimethoprim-sulfamethoxazole. Ann Intern Med 1980; 93: 560-2.
164. Boyd IW. Allopurinol-azathioprine interaction. J Intern Med 1991; 229: 386.
165. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994; 343: 1249-52.
166. Merker HJ, Pospisil M, Mewes P. Cytotoxic effects of 6-mercaptopurine on the limb-bud blastemal cells of rat embryos. Teratology 1975; 11: 199-217.
167. Williamson RA, Karp LE. Azathioprine teratogenicity: review of the literature and case report. Obstet Gynecol 1981; 58: 247-50.
168. Hou S. Pregnancy in organ transplant recipients. Med Clin North Am 1989; 73: 667-83.
169. Alstead EM, Ritchie RK, Lennard-Jones JE, Farthing MJG, Clark ML. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 1990; 99: 443-6.
170. Present DH. 6-mercaptopurine and other immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis. Gastroenterol Clin North Am 1989; 18: 57-71.
171. Coulam CB, Moyer TP, Jiang NS, Zincke H. Breast-feeding after renal transplantation. Transplant Proc 1982; 14: 605-9.
172. Grekas DM, Vasiliou SS, Lazarides AN. Immunosuppressive therapy and breast-feeding after renal transplantation. Nephron 1984; 37: 68.
173. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312: 818-22.
174. Healey LA. The current status of methotrexate use in rheumatoid arthritis. Bull Rheum Dis 1986; 36: 1-10.
175. Miller LC, Cohen SE, Orencole SF, et al. Interleukin-1 is structurally related to dihydrofolate reductase: effect of methotrexate on IL-1. Lymphokine Res 1988; 7: 272A.
176. Baron TH, Truss CD, Elson CO. Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig Dis Sci 1993; 38: 1851-6.
177. Kozarek PA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989; 110: 353-6.
178. Kozarek RA, Patterson DJ, Botoman VA, et al. Methotrexate use in inflammatory bowel disease patients who have failed azathioprine or 6-mercaptopurine. Gastroenterology 1991; 100: 222A.
179. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for treatment of Crohn's disease. N Engl J Med 1995; 332: 292-7.
180. Arora S, Katkov WN, Cooley J, et al. A double-blind, randomized, placebo-controlled trial of methotrexate in Crohn's disease. Gastroenterology 1992; 102: A591.
181. Al-Awadhi A, Dale P, McKendry RJR. Pancytopenia associated with low dose methotrexate therapy: a regional survey. J Rheum 1993; 20: 1121-5.
182. Morgan SL, Baggott JE, Vaughn WH, Austin JS, Veitch TA, Lee JY, Koopman WJ, Krumdieck CL, Alarcon GS. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double-blind, placebo-controlled trial. Ann Intern Med 1994; 121: 833-841.
183. Searles G, McKendry RJR. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheum 1987; 14: 1164-71.
184. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991; 90: 711-6.
185. Tshibangu K, Leroy F, Doumont-Meyvis M. Effeets of amethopterin (methotrexate) on the evolution of pregnancy in rats. Toxicology 1975; 4: 65-73.
186. Goldenberg M, Bider D, Admon D, Mashiach S, Oeslner G. Methotrexate therapy of tubal pregnancy. Hum Reprod 1993; 8: 660-6.
187. Bendtzen K, Petersen J. Effects of cyclosporin A (CyA) and methylprednisolone (MP) on the immune response. I. T-cell activating factor (IL-1) abrogates CyA- but not MP-induced suppression of antigen-induced lymphokine production. Immunol Lett 1982; 5: 79-83.
188. Hess AD, Tutschka PJ, Santos GW. Effect of cyclosporin on the induction of cytotoxic T lymphocytes: role of interleukin 1 and interleukin 2. Transplant Proc 1983; 15 (Suppl 1): 2248-58.
189. Kalman VK, Kumpel GR. Cyclosporin A inhibits the production of gamma interferon (IFN gamma), but does not inhibit production of virus induced IFN α/β. Cell Immunol 1983; 78: 122-9.
190. Wasik MA, Beller DI. Induction of macrophage membrane interleukin 1 expression by T-cell dependent and T-cell independent pathways is inhibited by cyclosporin A. Clin Immunol Immunopathol 1989; 52: 331-40.
191. Brynskov V, Freund L, Rasmussen SN, et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active Crohn's disease. N Engl J Med 1989; 321: 845-50.
192. Brynskov J, Freund L, Rasmussen SN, et al. Final report on a placebo-controlled, double-blind, randomized, multicentre trial of cyclosporin treatment in active Crohn's disease. Scand J Gastroenterol 1991; 26: 689-95.
193. Sandborn WJ. A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis (CCFA) 1995; 1: 48-63.
194. Brynskov J, Freund L, Campanini MC, Kampmann JP. Cyclosporin pharmacokinetics after intravenous and oral administration in patients with Crohn's disease. Scand J Gastroenterol 1992; 27: 961-7.
195. Jewell DP, Lennard-Jones JE. Oral cyclosporin for chronic active Crohn's disease: a multicentre controlled trial. The Cyclosporin Study Group of Great Britain and Ireland. Eur J Hepatol Gastroenterol 1994; 6: 499-505.
196. Hanauer SB, Smith MB. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A. Am J Gastroenterol 1993; 88: 646-9.
197. Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of tistula in Crohn's disease. Dig Dis Sci 1994; 39: 374-80.
198. Feagan BG, McDonald JW, Rochon J, et al. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators. N Engl J Med 1994; 330: 1846-51.
199. Lobo AJ, Juby LD, Rothwell J, Poole TW, Axon AT. Long-term treatment of Crohn's disease with cyclosporine: the effect of a very low dose on maintenance of remission. J Clin Gastroenterol 1991; 13: 42-5.
200. Lobo AJ, Juby LD, Smith AH, et al. Effect of oral cyclosporin on renal function in Crohn's disease. Dig Dis Sci 1993; 38: 1624-30.
201. Sandborn WJ, Tremaine WJ. Cyclosporin treatment of inflammatory bowel disease. Mayo Clin Proc 1992; 67: 981-90.
202. Cockburn ITR, Krupp P. The risk of neoplasms in patients treated with cyclosporine A. J Autoimmun 1989; 2: 723-31.
203. Armenti VT, Ahlswede KM, Ahlswede BA, Jarrell BE, Moritz MJ, Burke JF. National Transplantation Pregnancy Registry: outcomes of 154 pregnancies in cyclosporine-treated female kidney transplant recipients. Transplantation 1994; 57: 502-6.
204. Behrens O, Kohlaw K, Gunter H, Wonigeit K, Niesert S. Detection of cyclosporin A in breast milk: is breast feeding contraindicated? Geburtshilfe Frauendheilk 1989; 49: 207-9.
205. Reynolds JC, Trellis DR, Abu-Elmagd K, Fung J. The rationale for FK 506 in inflammatory bowel disease. Can J Gastroenterol 1993; 7: 208-10.
206. Langholz E, Brynskov J, Bendtzen K, Vilien M, Binder V. Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin. Aliment Pharmacol Ther 1992; 6: 495-502.
207. Levine DS, Fischer SH, Haggitt RC, Christie DL, Ochs HD. Intravenous immunoglobulin therapy for active, extensive. and medically refractory idiopathic ulcerative or Crohn's colitis. Am J Gastroenterol 1992; 87: 91-100.
208. Derkx B, Taminiau J, Radema S, et al. Tumour necrosis factor antibody treatment in Crohn's disease. Lancet 1993; 342: 173-4.
209. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentration of rumour necrosis factor a in childhood chronic inflammatory bowel disease. Gut 1991; 32: 913-7.
210. Remick DG, Kunkel RG, Larrick JW, et al. Acute in vivo effects of human recombinant tumour necrosis factor. Lab Invest 1987; 56: 583.
211. Stronkhorst A, Radema S, Ten Berge I, et al. Phase 1 multiple-dose pilot study of chimeric monoclonal M-T412 (anti CD4) antibodies in Crohn's disease. Gastroenterology 1993; 104: 784A.
212. Deutsch K, Mauthe B, Reiter C, Riethmuller G, Classen M. CD4-antibody treatment of inflammatory bowel disease. Gastroenterology 1993; 104: 691A.
213. Emmrich J, Seyfarth M, Fleig WE, Emmrich F. Treatment of inflammatory bowel disease with anti-CD4 monoclonal antibody. Lancet 1991; 1: 570-1.
214. Bicks RO, Groshart KD. The current status of T-lymphocyte apheresis (TLA) treatment of Crohn's disease. J Clin Gastroenterol 1989; 11: 136-8.
215. Cominelli F, Nast CC, Duchini A, Lee M. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology 1992; 103: 65-71.
216. Kroemer G, Wick G. The role of interleukin-2 in autoimmunity. Immunol Today 1989; 10: 246-51.
217. Moore KW, O'Garra A, De Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Ann Rev Immunol 1993; 11: 165-90.
218. Peppercorn MA. Is there a role for antibiotics as primary therapy in Crohn's Ileitis? J Clin Gastroenterol 1993; 17: 235-7.
219. Ursing B, Kamme C. Metronidazole for Crohn's disease. Lancet 1975; 1: 755-7.
220. Miller JJ. The imidazoles as immunosuppressive agents. Transplant Proc 1980; 12: 300-3.
221. Ursing B, Alm T, Bárány F. et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the Cooperative Crohn's Disease Study in Sweden. II. Result. Gastroenterology 1982; 83: 550-62.
222. Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo-controlled trial of metronidazole in Crohn's disease. Gut 1991; 32: 1071-5.
223. Bernstein LH, Frank MS, Brandt LJ, Boley SJ. Healing of perineal Crohn's disease with metronidazole. Gastroenterology 1980; 79: 357-65.
224. Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology 1982; 83: 383-7.
225. Jakobovits J, Schuster MM. Metronidazole therapy for Crohn's disease and associated flstulae. Am J Gastroenterol 1984; 79: 533-40.
226. Rutgeerts P, Peeters M, Hiele M, et al. A placebo controlled trial of metronidazole for recurrence prevention of Crohn's disease after resection of the terminal ileum. Gastroenterology 1992; 102: A688.
227. Gitnick D. Antibiotics and inflammatory bowel diseases. Gastroenterol Clin North Am 1989; 18: 51-6.
228. Duffy LF, Daum F, Fisher SE, et al. Peripheral neuropathy in Crohn's disease patients treated with metronidazole. Gastroenterology 1985; 88: 681-4.
229. Piper JM, Mitchel EF, Ray WA. Prenatal use of metronidazole and birth defects: no association. Obstet Gynecol 1993; 82: 348-52.
230. Moore B, Collier J. Drugs and breast feeding. BMJ 1979; 2: 211.
231. Turunen U, Färkkilä M, Valtonen V, Seppälä K. Long-term outcome of ciprofloxacin treatment in severe perianal or fistulous Crohn's disease. Gastroenterology 1993; 104: A793.
232. Solomon MJ, McLeod RS, O'Connor BI, Steinhart AH, Greenberg GR, Cohen Z. Combination ciprofloxacin and metronidazole in severe perianal Crohn's disease. Can J Gastroenterol 1993; 7: 571-3.
233. Peppercorn MA. Is there a role for antibiotics as primary therapy in Crohn's ileitis? J Clin Gastroenterol 1993; 17: 235-7.
234. Moss AA, Carbone JV, Kressel HY. Radiologic and clinical assessment of broad-spectrum antibiotic therapy in Crohn's disease. Am J Roentgenol 1978; 131: 787-90.
235. Rutgeerts P, Geboes K, Vantrappen G, et al. Rifabutin and ethambutol do not help recurrent Crohn's disease in the neoterminal ileum. J Clin Gastroenterol 1992; 15: 24-8.
236. Swift GL, Srivastava ED, Stone R, et al. Controlled trial of antituberculous chemotherapy for two years in Crohn's disease. Gut 1994; 35: 363-8.
237. Prantera C, Kohn A, Mangiarotti R, Andreoli A, Luzi C. Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol 1994: 5:513-8.
238. Matuchansky C. Parenteral nutrition in inflammatory bowel disease. Gut 1986; 27 (Suppl 1): 81-4.
239. Greenberg GR. Nutritional management of inflammatory bowel disease. Semin Gast Dis 1993; 4: 69-85.
240. Ostro MJ, Greenberg GR, Jeejeebhoy KN. Total parenteral nutrition and complete bowel rest in the management of Crohn's disease. J Parenter Enteral Nutr 1985; 9: 280-7.
241. Greenberg GR, Fleming CR, Jeejeebhoy KN, et al. Controlled trial of bowel rest and nutritional support in the management of Crohn's disease. Gut 1988; 29: 1309-15.
242. Seidman EG, Boutillier L, Weber AM, Roy CC, Morin CL. Elemental diet versus prednisone as primary treatment of Crohn's disease. Gastroenterology 1986; 90: A1625.
243. Gorard DA, Hunt JB, Payne-James JJ, et al. Initial response and subsequent course of Crohn's disease treated with elemental diet or prednisolone. Gut 1993; 34: 1198-202.
244. Sanderson IR, Udeen S, Davies PSW, Savage MO, Walker-Smith JA. Remission induced by an elemental diet in small bowel Crohn's disease. Arch Dis Child 1987; 61: 123-7.
245. Lochs H, Steinhardt HJ, Klaus-Wentz B, et al. Comparison of enteral nutrition and drug treatment in active Crohn's disease. Gastroenterology 1991; 101: 881-8.
246. Middleton SJ, Riordan AM, Hunter JO. Comparison of elemental and peptide-based diets in the treatment of acute Crohn's disease. Ital J Gastroenterol 1991; 23: 609.
247. Royall D, Kahan I, Baker JP, Allard JP, Habal FM, Jeejeebhoy KN. Clinical and nutritional outcome of an elemental versus semi-elemental diet in active Crohn's disease. Gastroenterology 1992; 102: A576.
248. Raouf AH, Hildrey V, Daniel J, et al. Enteral feeding as sole treatment for Crohn's disease: controlled trial of whole protein versus amino acid based feed and a case study of dietary challenge. Gut 1991; 32: 702-7.
249. Rigaud D, Cosnes J, Le Quintrec Y, et al. Controlled trial comparing two types of enteral nutrition in treatment of active Crohn's disease: elemental versus polymeric diet. Gut 1991; 32: 1492-7.
250. González-Huix F, de Léon R, Fernández-Bañares F, Esteve M, et al. Polymeric enteral diets as primary treatment of active Crohn's disease: a prospective steroid controlled trial. Gut 1993; 34: 778-82.
251. Fernández-Beñares F, Cabré F. González-Huix F, Gaassull MA. Enteral nutrition as primary therapy in Crohn's disease. Gut 1994; Suppl 1: S55-9.
252. Hirakawa H, Fukuda Y, Tanida N, Hosomi M, Shimoyama T. Home elemental enteral hyperalimentation (HEEH) for the maintenance of remission in patients with Crohn's disease. Gastroenterol Japonica 1993; 28: 379-84.
253. Alun Jones V, Dickinson RJ, Workman E, Wilson AJ, Freeman AH, Hunter JO. Crohn's disease: maintenance of remission by diet. Lancet 1985; 2: 177-80.
254. Pearson M, Teahon K, Levi AJ, Bjarnason I. Food intolerance and Crohn's disease. Gut 1993; 34: 783-7.
255. Barrett KE, Dharmsathaphorn K. Pharmacological aspects of therapy in inflammatory bowel diseases: antidiarrheal agents. J Clin Gastroenterol 1988; 10: 57-63.
256. Cottone M, Rosselli M, Orlando A, et al. Smoking habits and recurrence in Crohn's disease. Gastroenterology 1994; 106: 643-8.
257. Kaufmann HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 1987; 107: 513-6.
258. Laursen LS, Naesdal J, Bukhane K, Lauritsen K, Rask-Madsen J. Selective 5-lipoxygenase inhibitor in patients with ulcerative colitis. Gastroenterology 1990; 98: 185.
259. Emerit J, Loeper J, Chomette G. Superoxide dismutase in the treatment of post-radiotherapeutic necrosis and of Crohn's disease. Bull Eur Physiopathol Repair 1981; 17 (Suppl 32): 287-8.
260. Dickinson JB. Is omeprazole helpful in inflammatory bowel disease? J Clin Gastroenterol 1994; 18: 317-9.
261. Wellman W, Fink PC, Schmidt FW. Whole-gut irradiation as an antiendotoxinaemic therapy in inflammatory bowel disease. Hepatogastroenterology 1984; 31: 91-3.
262. Brady CE, Cooley BJ, Davis JC. Healing of severe perianal and cutaneous Crohn's disease with hyperbaric oxygen. Gastroenterology 1989; 97: 756-60.
263. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn's disease: a meta-analysis. Ann Intern Med 1995; 122: 132-12.
264. Softley A, Clamp SE, Watkinson G, Bouchier IAD, Myren J, De Dombal FT. The natural history of inflammatory bowel disease: has there been a change in the last 20 years? Scand J Gastroenterol 1988; Suppl 144: 20-3.